Related references
Note: Only part of the references are listed.Model-informed drug development: The mechanistic HSK3486 physiologically based pharmacokinetic model informing dose decisions in clinical trials of specific populations
Miao Zhang et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2023)
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator
Udoamaka Ezuruike et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)
Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
Chen Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
Matthew P. Gilbert et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Biopharmaceutic In Vitro In Vivo Extrapolation (IVIV_E) Informed Physiologically-Based Pharmacokinetic Model of Ritonavir Norvir Tablet Absorption in Humans Under Fasted and Fed State Conditions
Sumit Arora et al.
MOLECULAR PHARMACEUTICS (2020)
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Carolyn F. Deacon
NATURE REVIEWS ENDOCRINOLOGY (2020)
The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials
Shanshan Wu et al.
DIABETES OBESITY & METABOLISM (2019)
Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug
Shriram M. Pathak et al.
MOLECULAR PHARMACEUTICS (2017)
Renal Drug Transporters and Drug Interactions
Anton Ivanyuk et al.
CLINICAL PHARMACOKINETICS (2017)
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Merlin C. Thomas et al.
NATURE REVIEWS NEPHROLOGY (2016)
Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism
Bo Ahren et al.
DIABETOLOGIA (2016)
Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes
Christine Lin et al.
DRUG METABOLISM AND DISPOSITION (2016)
Reduction of glycine particle size by impinging jet crystallization
Timea Tari et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial
Jacob A. Udell et al.
DIABETES CARE (2015)
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Philippe A. Halban et al.
DIABETES CARE (2014)
Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
Yuliya Sharkovska et al.
JOURNAL OF HYPERTENSION (2014)
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
Per-Henrik Groop et al.
DIABETES CARE (2013)
Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?
Giuseppe Paolisso et al.
ADVANCES IN THERAPY (2012)
Glomerular hyperfiltration: definitions, mechanisms and clinical implications
Imed Helal et al.
NATURE REVIEWS NEPHROLOGY (2012)
Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats
Wei Jing Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Emerging evidence of the impact of kidney disease on drug metabolism and transport
T. D. Nolin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Clinical practice guidelines in nephrology: Evaluation, classification, and stratification of chronic kidney disease
GR Bailie et al.
PHARMACOTHERAPY (2005)
Drug therapy in the elderly
M Turnheim
EXPERIMENTAL GERONTOLOGY (2004)
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
T Vilsboll et al.
REGULATORY PEPTIDES (2003)
Share Paper
